{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,10]],"date-time":"2026-06-10T15:01:39Z","timestamp":1781103699534,"version":"3.54.1"},"reference-count":105,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2024,10,1]],"date-time":"2024-10-01T00:00:00Z","timestamp":1727740800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,10,1]],"date-time":"2024-10-01T00:00:00Z","timestamp":1727740800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,10,1]],"date-time":"2024-10-01T00:00:00Z","timestamp":1727740800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2024,10,1]],"date-time":"2024-10-01T00:00:00Z","timestamp":1727740800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2024,10,1]],"date-time":"2024-10-01T00:00:00Z","timestamp":1727740800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2024,10,1]],"date-time":"2024-10-01T00:00:00Z","timestamp":1727740800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2024,10,1]],"date-time":"2024-10-01T00:00:00Z","timestamp":1727740800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","theclinics.com","clinicalkey.es","clinicalkey.com.au","clinicalkey.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Hematology\/Oncology Clinics of North America"],"published-print":{"date-parts":[[2024,10]]},"DOI":"10.1016\/j.hoc.2024.05.006","type":"journal-article","created":{"date-parts":[[2024,7,8]],"date-time":"2024-07-08T07:07:49Z","timestamp":1720422469000},"page":"973-995","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":12,"title":["Targeted Therapy Innovations for Melanoma"],"prefix":"10.1016","volume":"38","author":[{"given":"Dahiana","family":"Amarillo","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Keith T.","family":"Flaherty","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ryan J.","family":"Sullivan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"6","key":"10.1016\/j.hoc.2024.05.006_bib1","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1038\/nrc.2016.37","article-title":"From melanocytes to melanomas","volume":"16","author":"Shain","year":"2016","journal-title":"Nature Rev Cancer"},{"issue":"1","key":"10.1016\/j.hoc.2024.05.006_bib2","doi-asserted-by":"crossref","first-page":"17","DOI":"10.3322\/caac.21763","article-title":"Cancer statistics, 2023","volume":"73","author":"Siegel","year":"2023","journal-title":"CA Cancer J Clin"},{"issue":"7","key":"10.1016\/j.hoc.2024.05.006_bib3","doi-asserted-by":"crossref","first-page":"776","DOI":"10.1001\/jamadermatol.2016.0050","article-title":"Human determinants and the role of melanocortin-1 receptor variants in melanoma risk independent of UV radiation exposure","volume":"152","author":"Pehamberger","year":"2016","journal-title":"JAMA Dermatol"},{"issue":"5","key":"10.1016\/j.hoc.2024.05.006_bib4","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1001\/jamadermatol.2022.0160","article-title":"Global burden of cutaneous melanoma in 2020 and projections to 2040","volume":"158","author":"Arnold","year":"2022","journal-title":"JAMA Dermatol"},{"issue":"12","key":"10.1016\/j.hoc.2024.05.006_bib5","doi-asserted-by":"crossref","first-page":"2856","DOI":"10.1158\/2159-8290.CD-22-0603","article-title":"Comparative genomics provides etiologic and biological insight into melanoma subtypes","volume":"12","author":"Newell","year":"2022","journal-title":"Cancer Discov"},{"issue":"19","key":"10.1016\/j.hoc.2024.05.006_bib6","doi-asserted-by":"crossref","first-page":"2373","DOI":"10.1038\/onc.2012.345","article-title":"MAP kinase signaling and inhibition in melanoma","volume":"32","author":"Sullivan","year":"2013","journal-title":"Oncogene"},{"issue":"2","key":"10.1016\/j.hoc.2024.05.006_bib7","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1097\/CCO.0b013e3282f5271c","article-title":"The MAPK pathway in melanoma","volume":"20","author":"Fecher","year":"2008","journal-title":"Curr Opin Oncol"},{"issue":"1","key":"10.1016\/j.hoc.2024.05.006_bib8","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1016\/j.cell.2017.06.009","article-title":"RAS Proteins and Their Regulators in Human Disease","volume":"170","author":"Simanshu","year":"2017","journal-title":"Cell"},{"key":"10.1016\/j.hoc.2024.05.006_bib9","doi-asserted-by":"crossref","unstructured":"Randic T., Kozar I., Margue C., et al., NRAS mutant melanoma: towards better therapies. Vol. 99, Cancer Treatment Reviews, 2021, W.B. Saunders Ltd. Available at: https:\/\/www.cancertreatmentreviews.com\/article\/S0305-7372(21)00086-4\/fulltext. Accessed June 30, 2024.","DOI":"10.1016\/j.ctrv.2021.102238"},{"key":"10.1016\/j.hoc.2024.05.006_bib10","doi-asserted-by":"crossref","unstructured":"Song Y., Bi Z., Liu Y., et al., Targeting RAS\u2013RAF\u2013MEK\u2013ERK signaling pathway in human cancer: current status in clinical trials. Vol. 10, Genes and Diseases, 2023, KeAi Communications Co, 76\u201388. Available at: https:\/\/www.sciencedirect.com\/science\/article\/pii\/S2352304222001404?via%3Dihub. Accessed June 30, 2024.","DOI":"10.1016\/j.gendis.2022.05.006"},{"issue":"7","key":"10.1016\/j.hoc.2024.05.006_bib11","doi-asserted-by":"crossref","first-page":"22","DOI":"10.3390\/ijms22073474","article-title":"BRAF Gene and Melanoma: Back to the Future","volume":"22","author":"Ottaviano","year":"2021","journal-title":"Int J Mol Sci"},{"issue":"5","key":"10.1016\/j.hoc.2024.05.006_bib12","doi-asserted-by":"crossref","first-page":"610","DOI":"10.1016\/j.ccell.2021.01.011","article-title":"Melanoma models for the next generation of therapies","volume":"39","author":"Patton","year":"2021","journal-title":"Cancer Cell"},{"issue":"5","key":"10.1016\/j.hoc.2024.05.006_bib13","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1038\/nrm2882","article-title":"The emerging mechanisms of isoform-specific PI3K signalling","volume":"11","author":"Vanhaesebroeck","year":"2010","journal-title":"Nat Rev Mol Cell Biol"},{"issue":"4","key":"10.1016\/j.hoc.2024.05.006_bib14","doi-asserted-by":"crossref","DOI":"10.3390\/biom9040153","article-title":"The PTEN\u2013PI3K Axis in Cancer","volume":"9","author":"Papa","year":"2019","journal-title":"Biomolecules"},{"issue":"9","key":"10.1016\/j.hoc.2024.05.006_bib15","doi-asserted-by":"crossref","first-page":"A413","DOI":"10.1016\/j.jval.2017.08.092","article-title":"Epidemiology of BRAFV600-mutated metastatic melanoma in Europe: A systematic review","volume":"20","author":"Rahhali","year":"2017","journal-title":"Value Health"},{"issue":"1","key":"10.1016\/j.hoc.2024.05.006_bib16","doi-asserted-by":"crossref","DOI":"10.1038\/s41467-023-36979-y","article-title":"The molecular and functional landscape of resistance to immune checkpoint blockade in melanoma","volume":"14","author":"Lim","year":"2023","journal-title":"Nat Commun"},{"issue":"7653","key":"10.1016\/j.hoc.2024.05.006_bib17","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1038\/nature22071","article-title":"Whole-genome landscapes of major melanoma subtypes","volume":"545","author":"Hayward","year":"2017","journal-title":"Nature"},{"key":"10.1016\/j.hoc.2024.05.006_bib18","first-page":"1","article-title":"BRAF in Melanoma: Pathogenesis, Diagnosis, Inhibition, and Resistance","volume":"2011","author":"Sullivan","year":"2011","journal-title":"J\u00a0Skin Cancer"},{"issue":"6","key":"10.1016\/j.hoc.2024.05.006_bib19","doi-asserted-by":"crossref","first-page":"1297","DOI":"10.1016\/j.ejca.2012.11.019","article-title":"Resistance to BRAF-targeted therapy in melanoma","volume":"49","author":"Sullivan","year":"2013","journal-title":"Eur J Cancer"},{"issue":"9","key":"10.1016\/j.hoc.2024.05.006_bib20","doi-asserted-by":"crossref","first-page":"791","DOI":"10.1158\/2159-8290.CD-12-0097","article-title":"BRAFL597 mutations in melanoma are associated with sensitivity to MEK inhibitors","volume":"2","author":"Dahlman","year":"2012","journal-title":"Cancer Discov"},{"key":"10.1016\/j.hoc.2024.05.006_bib21","first-page":"175","article-title":"Principles of Targeted Therapy for Melanoma","volume":"100","author":"Sun","year":"2020","journal-title":"Surg Clin"},{"issue":"1","key":"10.1016\/j.hoc.2024.05.006_bib22","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1158\/2159-8290.CD-13-0642","article-title":"Acquired resistance and clonal evolution in melanoma during BRAF inhibitor therapy","volume":"4","author":"Shi","year":"2014","journal-title":"Cancer Discov"},{"issue":"1","key":"10.1016\/j.hoc.2024.05.006_bib23","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1158\/2159-8290.CD-13-0617","article-title":"The genetic landscape of clinical resistance to RAF inhibition in metastatic melanoma","volume":"4","author":"Van Allen","year":"2013","journal-title":"Cancer Discov"},{"issue":"7","key":"10.1016\/j.hoc.2024.05.006_bib24","doi-asserted-by":"crossref","first-page":"1681","DOI":"10.1016\/j.cell.2015.05.044","article-title":"Genomic classification of cutaneous melanoma","volume":"161","author":"Akbani","year":"2015","journal-title":"Cell"},{"issue":"1","key":"10.1016\/j.hoc.2024.05.006_bib25","doi-asserted-by":"crossref","DOI":"10.3892\/etm.2020.9510","article-title":"Immunohistochemical study of CD117 in various cutaneous melanocytic lesions","volume":"21","author":"Radu","year":"2021","journal-title":"Exp Ther Med"},{"issue":"7","key":"10.1016\/j.hoc.2024.05.006_bib26","doi-asserted-by":"crossref","first-page":"562","DOI":"10.3349\/ymj.2020.61.7.562","article-title":"KIT and melanoma: biological insights and clinical implications","volume":"61","author":"Pham","year":"2020","journal-title":"Yonsei Med J"},{"issue":"23","key":"10.1016\/j.hoc.2024.05.006_bib27","doi-asserted-by":"crossref","first-page":"5807","DOI":"10.1158\/1078-0432.CCR-18-1156","article-title":"Emerging targeted therapy for tumors with NTRK fusion proteins","volume":"24","author":"Kheder","year":"2018","journal-title":"Clin Cancer Res"},{"issue":"12","key":"10.1016\/j.hoc.2024.05.006_bib28","first-page":"1387","article-title":"NTKR gene fusions in melanoma: detection, prevalence and potential therapeutic implications","volume":"18","author":"Forschner","year":"2020","journal-title":"JDDG J der Deutschen Dermatol Gesellschaft"},{"issue":"12","key":"10.1016\/j.hoc.2024.05.006_bib29","first-page":"1387","article-title":"NTRK gene fusions in melanoma: detection, prevalence and potential therapeutic implications","volume":"18","author":"Forschner","year":"2020","journal-title":"Journal der Deutschen Dermatologischen Gesellschaft"},{"issue":"6","key":"10.1016\/j.hoc.2024.05.006_bib30","doi-asserted-by":"crossref","first-page":"412","DOI":"10.1038\/nrc3521","article-title":"The emerging mutational landscape of G proteins and G-protein-coupled receptors in cancer","volume":"13","author":"O\u2019Hayre","year":"2013","journal-title":"Nat Rev Cancer"},{"issue":"6","key":"10.1016\/j.hoc.2024.05.006_bib31","doi-asserted-by":"crossref","first-page":"1524","DOI":"10.3390\/cancers12061524","article-title":"Update on GNA Alterations in Cancer: Implications for Uveal Melanoma Treatment","volume":"12","author":"Larrib\u00e8re","year":"2020","journal-title":"Cancers (Basel)"},{"issue":"6","key":"10.1016\/j.hoc.2024.05.006_bib32","doi-asserted-by":"crossref","first-page":"525","DOI":"10.1097\/CMR.0000000000000121","article-title":"GNAQ and GNA11 mutations in uveal melanoma","volume":"24","author":"Shoushtari","year":"2014","journal-title":"Melanoma Res"},{"issue":"26","key":"10.1016\/j.hoc.2024.05.006_bib33","doi-asserted-by":"crossref","first-page":"2507","DOI":"10.1056\/NEJMoa1103782","article-title":"Improved Survival with Vemurafenib in Melanoma with BRAF V600E Mutation","volume":"364","author":"Chapman","year":"2011","journal-title":"N\u00a0Engl J Med"},{"issue":"10","key":"10.1016\/j.hoc.2024.05.006_bib34","doi-asserted-by":"crossref","first-page":"2581","DOI":"10.1093\/annonc\/mdx339","article-title":"Vemurafenib in patients with BRAFV600 mutation-positive metastatic melanoma: Final overall survival results of the randomized BRIM-3 study","volume":"28","author":"Chapman","year":"2017","journal-title":"Ann Oncol"},{"issue":"9839","key":"10.1016\/j.hoc.2024.05.006_bib35","doi-asserted-by":"crossref","first-page":"358","DOI":"10.1016\/S0140-6736(12)60868-X","article-title":"Dabrafenib in BRAF-mutated metastatic melanoma: A multicentre, open-label, phase 3 randomised controlled trial","volume":"380","author":"Hauschild","year":"2012","journal-title":"Lancet"},{"issue":"5","key":"10.1016\/j.hoc.2024.05.006_bib36","doi-asserted-by":"crossref","first-page":"1315","DOI":"10.1016\/S1470-2045(18)30497-2","article-title":"Overall survival in patients with BRAF-mutant melanoma receiving encorafenib plus binimetinib versus vemurafenib or encorafenib (COLUMBUS): a multicentre, open-label, randomised, phase 3 trial","volume":"19","author":"Dummer","year":"2018","journal-title":"Lancet Oncol"},{"issue":"7","key":"10.1016\/j.hoc.2024.05.006_bib37","doi-asserted-by":"crossref","first-page":"1631","DOI":"10.1093\/annonc\/mdx176","article-title":"Dabrafenib plus trametinib versus dabrafenib monotherapy in patients with metastatic BRAF V600E\/K-mutant melanoma: long-term survival and safety analysis of a phase 3 study","volume":"28","author":"Long","year":"2017","journal-title":"Ann Oncol"},{"issue":"8","key":"10.1016\/j.hoc.2024.05.006_bib38","doi-asserted-by":"crossref","first-page":"871","DOI":"10.1200\/JCO.2015.62.9345","article-title":"Overall survival and durable responses in patients with BRAF V600-mutant metastatic melanoma receiving dabrafenib combined with trametinib","volume":"34","author":"Long","year":"2016","journal-title":"J\u00a0Clin Oncol"},{"issue":"20","key":"10.1016\/j.hoc.2024.05.006_bib39","doi-asserted-by":"crossref","first-page":"1867","DOI":"10.1056\/NEJMoa1408868","article-title":"Combined vemurafenib and cobimetinib in BRAF -mutated melanoma","volume":"371","author":"Garbe","year":"2014","journal-title":"N\u00a0Engl J Med"},{"issue":"9","key":"10.1016\/j.hoc.2024.05.006_bib40","doi-asserted-by":"crossref","first-page":"1248","DOI":"10.1016\/S1470-2045(16)30122-X","article-title":"Cobimetinib combined with vemurafenib in advanced BRAFV600-mutant melanoma (coBRIM): updated efficacy results from a randomised, double-blind, phase 3 trial","volume":"17","author":"Ascierto","year":"2016","journal-title":"Lancet Oncol"},{"issue":"7","key":"10.1016\/j.hoc.2024.05.006_bib41","doi-asserted-by":"crossref","first-page":"626","DOI":"10.1056\/NEJMoa1904059","article-title":"Five-Year Outcomes with Dabrafenib plus Trametinib in Metastatic Melanoma","volume":"381","author":"Robert","year":"2019","journal-title":"N\u00a0Engl J Med"},{"issue":"12","key":"10.1016\/j.hoc.2024.05.006_bib42","doi-asserted-by":"crossref","first-page":"1139","DOI":"10.1056\/NEJMoa2005493","article-title":"Five-year analysis of adjuvant dabrafenib plus trametinib in stage iii melanoma","volume":"383","author":"Dummer","year":"2020","journal-title":"N\u00a0Engl J Med"},{"issue":"19","key":"10.1016\/j.hoc.2024.05.006_bib43","doi-asserted-by":"crossref","first-page":"1813","DOI":"10.1056\/NEJMoa1708539","article-title":"Adjuvant dabrafenib plus trametinib in stage III BRAF -mutated melanoma","volume":"377","author":"Long","year":"2017","journal-title":"N\u00a0Engl J Med"},{"issue":"14","key":"10.1016\/j.hoc.2024.05.006_bib44","doi-asserted-by":"crossref","first-page":"1345","DOI":"10.1056\/NEJMoa1709684","article-title":"Overall survival with combined nivolumab and ipilimumab in advanced melanoma","volume":"377","author":"Wolchok","year":"2017","journal-title":"N\u00a0Engl J Med"},{"issue":"1","key":"10.1016\/j.hoc.2024.05.006_bib45","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1056\/NEJMoa2109970","article-title":"Relatlimab and nivolumab versus nivolumab in untreated advanced melanoma","volume":"386","author":"Tawbi","year":"2022","journal-title":"N\u00a0Eng J Med"},{"issue":"15","key":"10.1016\/j.hoc.2024.05.006_bib46","doi-asserted-by":"crossref","DOI":"10.3390\/cancers14153779","article-title":"Treatment of metastatic melanoma with a combination of immunotherapies and molecularly targeted therapies","volume":"14","author":"Rager","year":"2022","journal-title":"Cancers (Basel)"},{"issue":"10240","key":"10.1016\/j.hoc.2024.05.006_bib47","doi-asserted-by":"crossref","first-page":"1835","DOI":"10.1016\/S0140-6736(20)30934-X","article-title":"Atezolizumab, vemurafenib, and cobimetinib as first-line treatment for unresectable advanced BRAFV600 mutation-positive melanoma (IMspire150): primary analysis of the randomised, double-blind, placebo-controlled, phase 3 trial","volume":"395","author":"Gutzmer","year":"2020","journal-title":"Lancet"},{"issue":"1","key":"10.1016\/j.hoc.2024.05.006_bib48","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1016\/S1470-2045(22)00687-8","article-title":"Overall survival with first-line atezolizumab in combination with vemurafenib and cobimetinib in BRAFV600 mutation-positive advanced melanoma (IMspire150): second interim analysis of a multicentre, randomised, phase 3 study","volume":"24","author":"Ascierto","year":"2023","journal-title":"Lancet Oncol"},{"issue":"10105","key":"10.1016\/j.hoc.2024.05.006_bib49","doi-asserted-by":"crossref","first-page":"1853","DOI":"10.1016\/S0140-6736(17)31601-X","article-title":"Pembrolizumab versus ipilimumab for advanced melanoma: final overall survival results of a multicentre, randomised, open-label phase 3 study (KEYNOTE-006)","volume":"390","author":"Schachter","year":"2017","journal-title":"Lancet"},{"key":"10.1016\/j.hoc.2024.05.006_bib50","series-title":"Patterns of response and progression to immunotherapy","first-page":"169","author":"Borcoman","year":"2018"},{"issue":"2","key":"10.1016\/j.hoc.2024.05.006_bib51","doi-asserted-by":"crossref","first-page":"186","DOI":"10.1200\/JCO.22.01763","article-title":"Combination Dabrafenib and Trametinib Versus Combination Nivolumab and Ipilimumab for Patients With Advanced BRAF-Mutant Melanoma: The DREAMseq Trial ECOG-ACRIN EA6134","volume":"41","author":"Atkins","year":"2023","journal-title":"J\u00a0Clin Oncol"},{"issue":"2","key":"10.1016\/j.hoc.2024.05.006_bib52","doi-asserted-by":"crossref","first-page":"240","DOI":"10.1016\/j.ccell.2014.11.018","article-title":"Tunable-Combinatorial Mechanisms of Acquired Resistance Limit the Efficacy of BRAF\/MEK Cotargeting but Result in Melanoma Drug Addiction","volume":"27","author":"Moriceau","year":"2015","journal-title":"Cancer Cell"},{"key":"10.1016\/j.hoc.2024.05.006_bib53","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/ncomms6694","article-title":"Increased MAPK reactivation in early resistance to dabrafenib\/trametinib combination therapy of BRAF-mutant metastatic melanoma","volume":"5","author":"Long","year":"2014","journal-title":"Nat Commun"},{"issue":"3\u20134","key":"10.1016\/j.hoc.2024.05.006_bib54","doi-asserted-by":"crossref","first-page":"133","DOI":"10.5603\/NJO.2019.0025","article-title":"Mechanisms of melanoma resistance to treatment with BRAF and MEK inhibitors","volume":"69","author":"Bartnik","year":"2019","journal-title":"Nowotwory Journal of Oncology"},{"issue":"18","key":"10.1016\/j.hoc.2024.05.006_bib55","doi-asserted-by":"crossref","first-page":"2792","DOI":"10.1016\/j.ejca.2015.08.022","article-title":"Acquired BRAF inhibitor resistance: a multicenter meta-analysis of the spectrum and frequencies, clinical behavior, and phenotypic associations of resistance mechanisms","volume":"51","author":"Johnson","year":"2015","journal-title":"Eur J Cancer"},{"issue":"7","key":"10.1016\/j.hoc.2024.05.006_bib56","doi-asserted-by":"crossref","first-page":"1913","DOI":"10.1084\/jem.20171960","article-title":"Loss of USP28-mediated BRAF degradation drives resistance to RAF cancer therapies","volume":"215","author":"Saei","year":"2018","journal-title":"J\u00a0Exp Med"},{"issue":"1","key":"10.1016\/j.hoc.2024.05.006_bib57","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1158\/1541-7786.MCR-18-0327","article-title":"Hyperactivation of MAPK Signaling Is Deleterious to RAS\/RAF-mutant Melanoma","volume":"17","author":"Leung","year":"2019","journal-title":"Mol Cancer Res"},{"issue":"6","key":"10.1016\/j.hoc.2024.05.006_bib58","doi-asserted-by":"crossref","first-page":"849","DOI":"10.1053\/j.seminoncol.2015.09.023","article-title":"MEK1\/2 inhibitors: molecular activity and resistance mechanisms","volume":"42","author":"Wu","year":"2015","journal-title":"Semin Oncol"},{"issue":"MARCH2016","key":"10.1016\/j.hoc.2024.05.006_bib59","article-title":"Registered Report: COT drives resistance to RAF inhibition through MAP kinase pathway reactivation","volume":"5","author":"Sharma","year":"2016","journal-title":"Elife [Internet]"},{"issue":"3","key":"10.1016\/j.hoc.2024.05.006_bib60","doi-asserted-by":"crossref","first-page":"1164","DOI":"10.3892\/ijo.2016.3594","article-title":"Targeting the PI3K\/AKT\/mTOR pathway overcomes the stimulating effect of dabrafenib on the invasive behavior of melanoma cells with acquired resistance to the BRAF inhibitor","volume":"49","author":"Caporali","year":"2016","journal-title":"Int J Oncol"},{"issue":"5","key":"10.1016\/j.hoc.2024.05.006_bib61","doi-asserted-by":"crossref","first-page":"462","DOI":"10.15252\/embj.201592081","article-title":"Actin remodeling confers BRAF inhibitor resistance to melanoma cells through YAP\/TAZ activation","volume":"35","author":"Kim","year":"2016","journal-title":"EMBO J"},{"key":"10.1016\/j.hoc.2024.05.006_bib62","doi-asserted-by":"crossref","DOI":"10.1172\/JCI70156","article-title":"WNT5A enhances resistance of melanoma cells to targeted BRAF inhibitors","volume":"124","author":"Anastas","year":"2014","journal-title":"J\u00a0Clin Invest"},{"issue":"6","key":"10.1016\/j.hoc.2024.05.006_bib63","doi-asserted-by":"crossref","first-page":"1271","DOI":"10.1016\/j.cell.2015.07.061","article-title":"Non-genomic and Immune Evolution of Melanoma Acquiring MAPKi Resistance","volume":"162","author":"Hugo","year":"2015","journal-title":"Cell"},{"issue":"9","key":"10.1016\/j.hoc.2024.05.006_bib64","doi-asserted-by":"crossref","first-page":"8206","DOI":"10.18632\/oncotarget.23654","article-title":"Distinct histone modifications denote early stress-induced drug tolerance in cancer","volume":"9","author":"Emran","year":"2017","journal-title":"Oncotarget"},{"issue":"4","key":"10.1016\/j.hoc.2024.05.006_bib65","doi-asserted-by":"crossref","first-page":"1777","DOI":"10.7150\/thno.36218","article-title":"The \u201cART\u201d of Epigenetics in Melanoma: From histone \u201cAlterations, to Resistance and Therapies.\u201d","volume":"10","author":"Strub","year":"2020","journal-title":"Theranostics"},{"key":"10.1016\/j.hoc.2024.05.006_bib66","doi-asserted-by":"crossref","first-page":"348","DOI":"10.1016\/j.ejca.2021.08.015","article-title":"c-Kit inhibitors for unresectable or metastatic mucosal, acral or chronically sun-damaged melanoma: a systematic review and one-arm meta-analysis","volume":"157","author":"Steeb","year":"2021","journal-title":"Eur J Cancer"},{"issue":"22","key":"10.1016\/j.hoc.2024.05.006_bib67","doi-asserted-by":"crossref","first-page":"2327","DOI":"10.1001\/jama.2011.746","article-title":"KIT as a Therapeutic Target in Metastatic Melanoma","volume":"305","author":"Carvajal","year":"2011","journal-title":"JAMA"},{"issue":"21","key":"10.1016\/j.hoc.2024.05.006_bib68","doi-asserted-by":"crossref","first-page":"2904","DOI":"10.1200\/JCO.2010.33.9275","article-title":"Phase II, open-label, single-arm trial of imatinib mesylate in patients with metastatic melanoma harboring c-kit mutation or amplification","volume":"29","author":"Guo","year":"2011","journal-title":"J\u00a0Clin Oncol"},{"issue":"4","key":"10.1016\/j.hoc.2024.05.006_bib69","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1016\/S1470-2045(17)30180-8","article-title":"Binimetinib versus dacarbazine in patients with advanced NRAS-mutant melanoma (NEMO): a multicentre, open-label, randomised, phase 3 trial","volume":"18","author":"Dummer","year":"2017","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.hoc.2024.05.006_bib70","doi-asserted-by":"crossref","first-page":"1133","DOI":"10.3390\/cancers11081133","article-title":"Atypical BRAF and NRAS Mutations in Mucosal Melanoma","volume":"11","author":"Dumaz","year":"2019","journal-title":"Cancers"},{"issue":"1","key":"10.1016\/j.hoc.2024.05.006_bib71","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1007\/s10637-016-0391-2","article-title":"A\u00a0phase I dose-escalation study of TAK-733, an investigational oral MEK inhibitor, in patients with advanced solid tumors","volume":"35","author":"Adjei","year":"2017","journal-title":"Invest New Drugs"},{"issue":"9","key":"10.1016\/j.hoc.2024.05.006_bib72","doi-asserted-by":"crossref","first-page":"731e1498","DOI":"10.1002\/onco.13795","article-title":"Efficacy and safety of trametinib in non-V600 BRAF mutant melanoma: a phase II study","volume":"26","author":"Nebhan","year":"2021","journal-title":"Oncologist"},{"issue":"7494","key":"10.1016\/j.hoc.2024.05.006_bib73","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1038\/nature13121","article-title":"Reversible and adaptive resistance to BRAF(V600E) inhibition in melanoma","volume":"508","author":"Sun","year":"2014","journal-title":"Nature"},{"issue":"3","key":"10.1016\/j.hoc.2024.05.006_bib74","doi-asserted-by":"crossref","first-page":"573","DOI":"10.1016\/j.celrep.2019.09.009","article-title":"Genetic Heterogeneity of BRAF Fusion Kinases in Melanoma Affects Drug Responses","volume":"29","author":"Botton","year":"2019","journal-title":"Cell Rep"},{"issue":"5","key":"10.1016\/j.hoc.2024.05.006_bib75","doi-asserted-by":"crossref","first-page":"607","DOI":"10.1111\/pcmr.12388","article-title":"Clinical activity of the MEK inhibitor trametinib in metastatic melanoma containing BRAF kinase fusion","volume":"28","author":"Menzies","year":"2015","journal-title":"Pigment Cell Melanoma Res"},{"issue":"6","key":"10.1016\/j.hoc.2024.05.006_bib76","doi-asserted-by":"crossref","DOI":"10.1136\/bcr-2020-238494","article-title":"SKAP2-BRAF fusion and response to an MEK inhibitor in a patient with metastatic melanoma resistant to immunotherapy","volume":"14","author":"Chew","year":"2021","journal-title":"BMJ Case Rep"},{"issue":"33","key":"10.1016\/j.hoc.2024.05.006_bib77","doi-asserted-by":"crossref","first-page":"3142","DOI":"10.1200\/JCO.19.00489","article-title":"Targeted Therapy in Advanced Melanoma With Rare BRAF Mutations","volume":"37","author":"Menzer","year":"2019","journal-title":"J\u00a0Clin Oncol"},{"issue":"10","key":"10.1016\/j.hoc.2024.05.006_bib78","doi-asserted-by":"crossref","first-page":"2215","DOI":"10.1016\/j.bmc.2016.03.055","article-title":"Purinylpyridinylamino-based DFG-in\/\u03b1C-helix-out B-Raf inhibitors: Applying mutant versus wild-type B-Raf selectivity indices for compound profiling","volume":"24","author":"Liu","year":"2016","journal-title":"Bioorg Med Chem"},{"issue":"3","key":"10.1016\/j.hoc.2024.05.006_bib79","doi-asserted-by":"crossref","first-page":"384","DOI":"10.1016\/j.ccell.2015.08.002","article-title":"Inhibition of RAF Isoforms and Active Dimers by LY3009120 Leads to Anti-tumor Activities in RAS or BRAF Mutant Cancers","volume":"28","author":"Peng","year":"2015","journal-title":"Cancer Cell"},{"key":"10.1016\/j.hoc.2024.05.006_bib80","article-title":"Mediator Kinase Inhibition Impedes Transcriptional Plasticity and Prevents Resistance to ERK\/MAPK-Targeted Therapy in KRAS-Mutant Cancers","author":"Wood","year":"2023","journal-title":"Res Sq [Internet]"},{"issue":"8","key":"10.1016\/j.hoc.2024.05.006_bib81","doi-asserted-by":"crossref","first-page":"1904","DOI":"10.1002\/cam4.1140","article-title":"A\u00a0first-in-human phase I, multicenter, open-label, dose-escalation study of the oral RAF\/VEGFR-2 inhibitor (RAF265) in locally advanced or metastatic melanoma independent from BRAF mutation status","volume":"6","author":"Izar","year":"2017","journal-title":"Cancer Med [Internet]"},{"issue":"19","key":"10.1016\/j.hoc.2024.05.006_bib82","doi-asserted-by":"crossref","first-page":"2140","DOI":"10.1200\/JCO.19.02654","article-title":"Phase I, Open-Label, Dose-Escalation\/Dose-Expansion Study of Lifirafenib (BGB-283), an RAF Family Kinase Inhibitor, in Patients With Solid Tumors","volume":"38","author":"Desai","year":"2020","journal-title":"J\u00a0Clin Oncol [Internet]"},{"issue":"2","key":"10.1016\/j.hoc.2024.05.006_bib83","doi-asserted-by":"crossref","first-page":"460","DOI":"10.1158\/1535-7163.MCT-19-0681","article-title":"A\u00a0Phase I Study of LY3009120, a Pan-RAF Inhibitor, in Patients with Advanced or Metastatic Cancer","volume":"19","author":"Sullivan","year":"2020","journal-title":"Mol Cancer Ther"},{"issue":"3","key":"10.1016\/j.hoc.2024.05.006_bib84","doi-asserted-by":"crossref","first-page":"714","DOI":"10.1158\/2159-8290.CD-20-0873","article-title":"Durable suppression of acquired mek inhibitor resistance in cancer by sequestering mek from erk and promoting antitumor t-cell immunity","volume":"11","author":"Hong","year":"2021","journal-title":"Cancer Discov"},{"issue":"6","key":"10.1016\/j.hoc.2024.05.006_bib85","doi-asserted-by":"crossref","first-page":"821","DOI":"10.1038\/onc.2017.384","article-title":"RAF inhibitor LY3009120 sensitizes RAS or BRAF mutant cancer to CDK4\/6 inhibition by abemaciclib via superior inhibition of phospho-RB and suppression of cyclin D1","volume":"37","author":"Chen","year":"2018","journal-title":"Oncogene"},{"key":"10.1016\/j.hoc.2024.05.006_bib86","article-title":"A\u00a0first-in-human, phase 1a\/1b, open-label, dose-escalation and expansion study to investigate the safety, pharmacokinetics, and antitumor activity of the RAF dimer inhibitor BGB-3245 in patients with advanced or refractory tumors","author":"Schram","year":"2023","journal-title":"AACR Annual Meeting"},{"issue":"8_Supplement","key":"10.1016\/j.hoc.2024.05.006_bib87","doi-asserted-by":"crossref","first-page":"CT033","DOI":"10.1158\/1538-7445.AM2023-CT033","volume":"83","author":"Solomon","year":"2023","journal-title":"Cancer Res [Internet]"},{"issue":"suppl_7","key":"10.1016\/j.hoc.2024.05.006_bib88","first-page":"S808","article-title":"Phase II study of multiple LXH254 drug combinations in patients (pts) with unresectable\/metastatic, BRAF V600- or NRAS-mutant melanoma","volume":"33","author":"Lebbe","year":"2022","journal-title":"Ann Oncol"},{"issue":"2","key":"10.1016\/j.hoc.2024.05.006_bib89","doi-asserted-by":"crossref","DOI":"10.1242\/dmm.049229","article-title":"RAS pathway regulation in melanoma","volume":"15","author":"Al Mahi","year":"2022","journal-title":"Dis Model Mech"},{"issue":"13","key":"10.1016\/j.hoc.2024.05.006_bib90","doi-asserted-by":"crossref","first-page":"1207","DOI":"10.1056\/NEJMoa1917239","article-title":"KRASG12C Inhibition with Sotorasib in Advanced Solid Tumors","volume":"383","author":"Hong","year":"2020","journal-title":"N\u00a0Engl J Med"},{"issue":"1","key":"10.1016\/j.hoc.2024.05.006_bib91","first-page":"1","article-title":"First-in-human phase I dose-escalation and dose-expansion trial of the selective MEK inhibitor HL-085 in patients with advanced melanoma harboring NRAS mutations","volume":"21","author":"Wang","year":"2023","journal-title":"BMC Med"},{"key":"10.1016\/j.hoc.2024.05.006_bib92","doi-asserted-by":"crossref","first-page":"S790","DOI":"10.1016\/j.annonc.2023.09.2411","article-title":"Efficacy and safety of tunlametinib (HL-085) combined with vemurafenib in patients with advanced BRAF V600-mutated solid tumors: A multicenter, phase I study","volume":"34","author":"Shi","year":"2023","journal-title":"Ann Oncol"},{"key":"10.1016\/j.hoc.2024.05.006_bib93","doi-asserted-by":"crossref","unstructured":"Si L, Zou Z, Zhang W, et\u00a0al. Efficacy and safety of tunlametinib in patients with advanced NRAS-mutant melanoma: A multicenter, open-label, single-arm, phase 2 study. 2023;41(16_suppl):9510\u20139510. Available at: https:\/\/ascopubs.org\/doi\/10.1200\/JCO.2023.41.16_suppl.9510.","DOI":"10.1200\/JCO.2023.41.16_suppl.9510"},{"key":"10.1016\/j.hoc.2024.05.006_bib94","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1016\/j.ejca.2022.08.005","article-title":"A\u00a0first-in-human, phase 1a dose-escalation study of the selective MEK1\/2 inhibitor FCN-159 in patients with advanced NRAS-mutant melanoma","volume":"175","author":"Mao","year":"2022","journal-title":"Eur J Cancer"},{"issue":"2","key":"10.1016\/j.hoc.2024.05.006_bib95","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1158\/2159-8290.CD-17-1119","article-title":"First-in-Class ERK1\/2 Inhibitor Ulixertinib (BVD-523) in Patients with MAPK Mutant Advanced Solid Tumors: Results of a Phase I Dose-Escalation and Expansion Study","volume":"8","author":"Sullivan","year":"2018","journal-title":"Cancer Discov"},{"issue":"3","key":"10.1016\/j.hoc.2024.05.006_bib96","doi-asserted-by":"crossref","first-page":"785","DOI":"10.1007\/s10637-020-01035-9","article-title":"Characterization and management of ERK inhibitor associated dermatologic adverse events: analysis from a nonrandomized trial of ulixertinib for advanced cancers","volume":"39","author":"Wu","year":"2021","journal-title":"Invest New Drugs"},{"issue":"15_suppl","key":"10.1016\/j.hoc.2024.05.006_bib97","first-page":"10036","article-title":"A\u00a0phase II study of ERK inhibition by ulixertinib (BVD-523) in metastatic uveal melanoma","volume":"38","author":"Buchbinder","year":"2020","journal-title":"Cancer Res Commun"},{"issue":"3","key":"10.1016\/j.hoc.2024.05.006_bib98","doi-asserted-by":"crossref","first-page":"380","DOI":"10.1007\/s10637-022-01326-3","article-title":"Results of an open-label phase 1b study of the ERK inhibitor MK-8353 plus the MEK inhibitor selumetinib in patients with advanced or metastatic solid tumors","volume":"41","author":"Stathis","year":"2023","journal-title":"Invest New Drugs"},{"issue":"79","key":"10.1016\/j.hoc.2024.05.006_bib99","doi-asserted-by":"crossref","first-page":"34990","DOI":"10.18632\/oncotarget.26204","article-title":"MEK\/CDK4,6 co-targeting is effective in a subset of NRAS, BRAF and \u201cwild type\u201d melanomas","volume":"9","author":"Posch","year":"2018","journal-title":"Oncotarget"},{"key":"10.1016\/j.hoc.2024.05.006_bib100","doi-asserted-by":"crossref","first-page":"v117","DOI":"10.1093\/annonc\/mdz242.026","article-title":"A\u00a0phase II study of abemaciclib in patients (pts) with brain metastases (BM) secondary to non-small cell lung cancer (NSCLC) or melanoma (MEL)","volume":"30","author":"Sahebjam","year":"2019","journal-title":"Ann Oncol"},{"issue":"10","key":"10.1016\/j.hoc.2024.05.006_bib101","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1016\/j.tibs.2013.08.001","article-title":"Hsp70 chaperone dynamics and molecular mechanism","volume":"38","author":"Mayer","year":"2013","journal-title":"Trends Biochem Sci"},{"key":"10.1016\/j.hoc.2024.05.006_bib102","doi-asserted-by":"crossref","first-page":"537","DOI":"10.1038\/nrc2887","article-title":"Targeting the dynamic HSP90 complex in cancer","volume":"10","author":"Trepel","year":"2010","journal-title":"Nat Rev Cancer"},{"key":"10.1016\/j.hoc.2024.05.006_bib103","doi-asserted-by":"crossref","unstructured":"Eroglu Z., Chen Y.A., Smalley I., et al., Combined BRAF, MEK, and heat-shock protein 90 (HSP90) inhibition in advanced BRAF V600-mutant melanoma, Cancer, 2023, Available at: https:\/\/acsjournals.onlinelibrary.wiley.com\/doi\/10.1002\/cncr.35029. Accessed June 30, 2024.","DOI":"10.1002\/cncr.35029"},{"issue":"4","key":"10.1016\/j.hoc.2024.05.006_bib104","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1158\/2159-8290.CD-15-0222","article-title":"Targeting autophagy in BRAF-mutant tumors","volume":"5","author":"Thorburn","year":"2015","journal-title":"Cancer Discov"},{"issue":"16_suppl","key":"10.1016\/j.hoc.2024.05.006_bib105","doi-asserted-by":"crossref","first-page":"9511","DOI":"10.1200\/JCO.2023.41.16_suppl.9511","article-title":"Randomized phase II trial of dabrafenib and trametinib with or without navitoclax in patients (pts) with BRAF-mutant (MT) metastatic melanoma (MM) (CTEP P9466)","volume":"41","author":"Eroglu","year":"2023","journal-title":"J\u00a0Clin Oncol"}],"container-title":["Hematology\/Oncology Clinics of North America"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0889858824000558?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0889858824000558?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,8,30]],"date-time":"2024-08-30T20:24:06Z","timestamp":1725049446000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0889858824000558"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,10]]},"references-count":105,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2024,10]]}},"alternative-id":["S0889858824000558"],"URL":"https:\/\/doi.org\/10.1016\/j.hoc.2024.05.006","relation":{},"ISSN":["0889-8588"],"issn-type":[{"value":"0889-8588","type":"print"}],"subject":[],"published":{"date-parts":[[2024,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Targeted Therapy Innovations for Melanoma","name":"articletitle","label":"Article Title"},{"value":"Hematology\/Oncology Clinics of North America","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.hoc.2024.05.006","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}